Expression and functional activity of P-glycoprotein in adult acute myelogenous leukemia patients

Annals of Hematology

Volumn 75, Issue 1-2, 1997, Pages 17-26

  Nuessler, V ^a   Gullis, E ^b   Pelka Fleischer, R ^a   Del Valle, F ^c   Diem, H ^a   Beyerlein, S ^a   Zwierzina, H ^d   Wilmanns, W ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c KLINIKUM OLDENBURG   (Germany)

^d UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Acute myelogenious leukemia; Chemotherapyresistance; Multidrug resistance; P glycoprotein; Rhodamin 123 assay

Indexed keywords

CD34 ANTIGEN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; IDARUBICIN; MONOCLONAL ANTIBODY; RHODAMINE 123; VERAPAMIL; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANTIGEN ANTIBODY REACTION; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RELAPSE;

ACUTE DISEASE; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; NEOPLASM PROTEINS; P-GLYCOPROTEIN; REMISSION INDUCTION;

EID: 0030818470     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050307     Document Type: Article

References (77)

1. Abbaszadegan MR, Futscher BW, Klimecki WT, List A, Dalton WS (1994) Analysis of multidrug resistance associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells. Cancer Res 54:4676-4679
2. Arceci RJ, Stiegliz K, Bras J, Schinkel A, Baas F, Croop J (1993) Monoclonal antibody to an external epitope of the human mdrl P-glycoprotein. Cancer Res 53:310-317
3. Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI (1994) Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 12:835-842
4. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyett JM, Brophy NA, Broxterman HJ, Chan HSL, Dalton WS, Dietel M, Fojo AT, Gascoyne RD, Head D, Houghton PJ, Srivastava DK, Lehnert M, Leith CP, Paietta E, Pavelic ZP, Rimsza L, Roninson IB, Sikic BI, Twentyman PR, Warnke R, Weinstein R (1996) Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 56:3010-3020
5. Benson AB, Trump DL, Koeller MI, Olmar EA, Witte RS, Tormey DC (1985) Phase I study of vinblastine and verapamil given by concurrent iv infusion. Cancer Treat Rep 69:795-799
6. Berman E, McBride M (1992) Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 79:3267-3273
7. Bielack S, Bode U, Groebel M, Gutjahr P, Haas R, Kuhn N, et al. (1992) Oral idarubicin in pretreated pediatric acute leukemia. Haematol Blood Transf 43:486-490
8. Burger H, Nooter K, Sonneveld P, van Wingerden K, Zaman GJR, Stoter G (1994) High expression of the multidrug resistance-associated protein (MRP) in chronic and prolymphocytic leukemia. Br J Haematol 88:348-356
9. Cairo MS, Siegel S, Anas N, Sender L (1989) Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatric tumors. Cancer Res 49:1063
10. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuro T, Troncy J, Treille D, Fiere D (1992) Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 79:473-476
11. Chaudhary PM, Roninson IB (1991) Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66:85-94
12. Chen C, Chin J, Ueda K, et al (1986) Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug resistant human cells. Cell 47:381-389
13. Chin KV, Pastan I, Gottesman MM (1993) Function and regulation of the human multidrug resistance gene. Adv Cancer Res 60:157-180
14. Christen RD, McClay EF, Plaxe SC, Yen SS, Kim S, Kirmani S, Wilgus LL, Heath DD, Shalinski DR, Freddo JL, Braly PS, O'Quigley J, Howell SB (1993) Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin. J Clin Oncol 11:2417-2426
15. Cole SPC, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, Deeley RG (1994) Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54:5902-5910
16. Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BGM, Taylor CW, Miller PT, Salmon SE (1989) Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7:415-424
17. de Boekhorst PA, de Leeuw K, Schoester M, Wittebol S, Nooter K, Hagemeijer A, Lowenberg B, Sonneveld P (1993) Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells. Blood 82:3157-3162
18. Del Poeta G, Stasi R, Venditti A, Suppo G, Aronica G, Bruno A, Masi M, Tabilio A, Papa G (1994) Prognostic value of cell marker analysis in de novo acute myeloid leukemia. Leukemia 8:388-394
19. Endicott JA, Ling V (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. Ann Rev Biochem 58:137-171
20. Erlichman C, Moore M, Thiessen JJ, Kerr IG, Walker S, Goodman P, Bjarnason G, DeAngelis S, Bunting P (1993) Phase I pharmacokinetic study of cyclosporin-A combined with doxorubicin. Cancer Res 53:4837-4842
21. Flens MJ, Izquierdo MA, Scheffer GL, Fritz JM, Meijer CJLM, Scheper RJ, Zaman GJR (1994) Immunochemical detection of the multidrug resistance associated protein MRP in human multidrug resistant tumor cells by monoclonal antibodies. Cancer Res 54:4557-4563
22. Geller RB, Zahurak M, Hurwitz CA, Burke PJ, Karp JE, Piantadosi S, Civin CI (1990) Prognostic importance of immunophenotyping in adults with acute myelocytic leukemia: the significance of the stem-cell glycoprotein CD34 (My10). Br J Haematol 76:340-347
23. Gerlach JH, Endicott JA, Juranka PF, et al (1986) Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature 324:485-489
24. Gieseler F, Biersack H, Brieden T, Manderscheid J, Nüssler V (1994) Cytotoxicity of anthracyclines: correlation with cellular uptake, intracellular distribution and DNA binding. Ann Hematol 69:13-17
25. Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem 62:385-427
26. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC Deeley RG (1994) Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54:357-361
27. Gros P, Neriah YB, Croop JM, Houseman DE (1986) Isolation and expression of a cDNA (mdr) that confers multidrug resistance. Nature 323:728-731
28. Gruber A, Vitols S, Norgren S, Arestrom I, Peterson C, Bjorkholm M, Reizenstein P, Luthman H (1992) Quantitative determination of mdr1 gene expression in leukaemic cells from patients with acute leukaemia. Br J Cancer 66:266-272
29. r 190,000 multidrug resistance protein, MRP, with monoclonal antibodies. Cancer Res 54:5788-5792
30. Holmes J, Jacobs A, Carter G, Janowska Wieczorek A, Padua RA (1989) Multidrug resistance in haemopoietic cell lines, myelodysplastic syndromes and acute myeloblastic leukaemia. Br J Haematol 72:40-44
31. Hunault M, Zhou D, Delmer A, Ramond S, Viguié F, Cadiou M, Perrot J-Y, Levy V, Rio B, Cymbalista F, Zittoun R, Marie J-P (1997) Multidrug resistance gene expression in acute myeloid leukemia: major prognosis significance for in vivo drug resistance to induction treatment. Ann Hematol 74:65-71
32. Ito Y, Tanimoto M, Kumazawa T, Okumura M, Morishima Y, Ohno R, Saito H (1989) Increased P-glycoprotein expression and multidrug-resistant gene (mdr1) amplification are infrequently found in fresh acute leukemia cells. Sequential analysis of 15 cases at initial presentation and relapsed stage. Cancer 63:1534-1538
33. Izquierdo MA, Scheffer GL, Flens MJ, Schroeijers AB, van der Kalk P, Scheper RJ (1996) Major vault protein LRP-related multidrug resistance. Eur J of Cancer 6:979-984
34. Jones RD, Kerr DJ, Harnett AN, Rankin EM, Ray S, Kaye SB (1990) A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer. Br J Cancer 62:133-135
35. Keating MJ, Cork A, Broach Y, Smith T, Walters RS, McCredie KB, Trujillo J, Freireich EJ (1987) Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia. Leukemia Res 11:119-133
36. Krishnamachary N, Liangdong M, Zheng L, Safa AR, Center MS (1994) Analysis of MRP gene expression and function in HL60 cells isolated for resistance to adriamycin. Onco Res 3:119-127
37. Kruth GD, Chan A, Myers K, Gaughan K, Miki T, Aaronson SA (1994) Expression complementary DNA library transfer establishes mrp as a multidrug resistance gene. Cancer Res 54:1649-1652
38. Kuffel MJ, Ames MM (1995) Comparative resistance of idarubicin, doxorubicin and their C-13 alcohol metabolites in human MDR1 transfected NIH-3T3 cells. Cancer Chemother Pharmacol 36:223-226
39. Kuwazuru Y, Yoishimura A, Hanada S, Utsunomiya A, Makino T, Ishibashi K, Kodama M, Iwahashi M, Arima T, Akiyama S (1990) Expression of the multidrug transporter, P-glycoprotein, in acute leukemia cells and correlation to clinical drug resistance. Cancer 66:868-873
40. +/Efflux Cases. Blood 86:2329-2342
41. Linn SC, van Kalken CK, van Tellingen O, van der Valk P, van Groeningen CJ, Kuiper CM, Pinedo HM, Giaccone G (1994) Clinical and pharmacologic study of multidrug resistance reversal with vinblastine and bepridil. J Clin Oncol 12:812-819
42. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Baier M, Dalton W (1993) Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 11:1652-1660
43. Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP, Sikic BI (1992) Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10:1635-1642
44. Marie JP, Zittoun R, Sikic BI (1991) Multidrug resistance (mdr1) gene expression in adult leukemia:correlation with treatment outcome and in vitro drug sensitivity. Blood 78:586-592
45. Marie JP, Bastie JN, Coloma F, Faussat Suberville AM, Delmer A, Rio B, Delmas-Marsalet B, Leroux G, Casassus P, Baumelou E, Catalin J, Zittoun R (1993) Cyclosporin-A as a modifier agent in the salvage treatment of acute leukemia (AL). Leukemia 7:821-824
46. Maslak P, Hegewisch Becker S, Godfrey l, Andreeff M (1994) Flow-cytometric determination of the multidrug resistant phenotype in acute leukemia. Cytometry 17:84-93
47. Michieli M, Damiani D, Geromin A, Michelutti A, Fanin R, Raspadori D, Russo D, Visani G, Dinota A, Pileri S, et al (1992) Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukemia. Eur J Haematol. 48:87-92
48. Miller RL, Bukowski RM, Budd GT, Purvis J, Weick JK, Shepard K, Ganapathi R (1988) Clinical modulation of doxorubicin resistance by the calmodulin inhibitor, trifluoperazine: a Phase I/II trial. J Clin Oncol 6:880-888
49. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE (1991) P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9:17-24
50. Miwa H, Kita K, Nishii K, Morita N, Takakura N, Ohishi K, Mahmud N, Kageyama S, Fukumoto M, Shirakawa S (1993) Expression of MDR1 gene in acute leukemia cells: association with CD7+ acute myeloblastic leukemia/acute lymphoblastic leukemia. Blood 82:3445-3451
51. Müller MR, Lennartz K, Boogen C, Nowrousian MR, Rajewski MF, Seeber S (1992) Cytotoxicity of adriamycin, idarubicin, and vincristine in acute myeloid leukemia: chemosensitization by verapamil in relation to P-glycoprotein expression. Ann Hematol 65:206-212
52. Musto P, Melillo L, Lombardi G, Matera R, Di Giorgio G, Carotenuto M (1991) High risk of early resistant relapse for leukemic patients with presence of multidrug resistance associated P-glycoprotein-positive cells in complete remission. Br J Haematol 77:50-53
53. Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL, Gazdar AF, Willman CL, Griffith B, Von Hoff DD, et al (1990) Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A 87:7160-7164
54. Nüssler V, Pelka Fleischer R, Zwierzina H, Nerl C, Beckert B, Gieseler F, Diem H, Ledderose G, Gullis E, Sauer H, Wilmanns W (1996) P glycoprotein expression in patients with acute leukemia: clinical relevance. Leukemia 10 [Suppl]:23-31
55. Nüssler V, Gieseler F, Zwierzina H, Gullis E, Pelka-Fleischer R, Diem H, Abenhardt W, Schmitt R, Langenmayer I, Wohlrab A, Kolb HJ, Wilmanns W (1997) Idarubicin monotherapy in multiply pretreated leukemia patients: response in relation to P-glycoprotein expression. Ann Hematol 74:57-64
56. Nuessler V, Scheulen ME, Oberneder R, Kriegmair M, Goebel KJ, Rathgeb F, Wurst W, Zech K, Wilmanns W (1997) Phase I and pharmacokinetic study of the P-glycoprotein modulator dexniguldipine-HCL. Eur J Med Res 2:55-61
57. Ozols RF, Cunnion RE, Klecker RW Jr, Hamilton TC, Ostchega Y, Young RC (1987) Verapamil and adriamycin in the treatment of drug-resistent ovarian cancer patients. J Clin Oncol 5:641-647
58. Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P, Hopfner M, Scherrer R, Valent P, Havelec L, et al (1991) MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 83:708-712
59. Presant CA, Kennedy PS, Wiseman C, Gala K., Bouzaglou A., Wyres M (1986) Verapamil reversal of clinical doxorubicin resistance in human cancer. A Wiltshire Oncology Medical Group pilot phase I-II study. Am J Clin Oncol 9:355-357
60. Salmon SE, Dalton WS, Grogan TM, Plezia P, Lehnert M, Roe DJ, Miller TP (1991) Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 78:44-50
61. Samuels BL, Mick R, Vogelzang NJ, Williams SF, Schilsky RL, Safa AR, Ratain MJ (1993) Modulation of vinblastine resistance with cyclosporine: a phase I study. Clin Pharmacol Ther 54:421-429
62. Scheffer GL, Wijngaard PLJ, Flens MJ, et al (1995) The drug resistance-related protein LRP is the human major vault protection. Nature Med 1:578-582
63. r 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 53:1475-1479
64. Schuurhuis GJ, Broxterman HJ, Ossenkoppele GJ, Baak JPA, Eekman CA, Kiper CM, Feller N, van Heijnigen THM, Klumper E, Pieters R, Lankelma J, Pinedo HM (1995) Functional multidrug resistance phenotype associated with combined overexpression of P-gp/MRP together with 1 b D-arabinofuranosylcytosine sensitivity may predict myeloid leukemia. Clin Cancer Res 1:81-93
65. Slapak CA, Fracasso PM, Martell RL, Toppmeyer DL, Lecerf J-M, Levy SB (1994) Overexpression of the multidrug resistance-associated protein (MRP) gene in vincristine but not doxorubicin-selected multidrug-resistant murine erythroleukemia cells. Cancer Res 54:5607-5613
66. Solary E, Caillot D, Chauffert B, Casasnovas RO, Dumas M, Maynadie M (1992) Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J Clin Oncol 10:1730-1736
67. Sonneveld P, Durie BG, Lokhorst HM, Marie JP, Solbu G, Suciu S, Lowenberg B, Nooter K (1992) Modulation of multi-drug-resistant multiple myeloma by cyclosporin-A. The Leukaemia Group of the EORTC and the HOVON. Lancet 340:255-259
68. Tidefelt U, Sundman-Engbert B, Paul C (1994) Comparison of the intracellular pharmacokinetics of daunorubicin and idarubicin in patients with acute leukemia. Leukemia Res 18:293-297
69. Tiirikainen MI, Elonen E, Ruutu T, Jansson SE, Krusius T (1993) Clinical significance of P-glycoprotein expression in acute leukaemia as analysed by immunocytochemistry. Eur J Haematol 50:279-285
70. Toffoli G, Simone F, Gigante M, Boiocchi M (1994) Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo Cell Lines. Biochem Pharmacol 10:1871-1881
71. Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, Winer EP, Jordan VC, Fine RL (1992) High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst 84:1811-1816
72. + AML cases. Blood 78 [Suppl]:172A
73. Wood P, Burgess R, MacGregor A, Yin JAL (1994) P-glycoprotein expression on acute myeloid leukemia blast cells at diagnosis predicts response to chemotherapy and survival. Br J Haematol 87:509-514
74. Young IT (1977) Proof without prejudice: use of the Kolmogorov Smirnov test for the analysis of histograms from flow systems and other sources. J Histochem Cytochem 25:935-941
75. Zaman GJR, Flens MJ, van Leusden MR, et al (1994) The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci U S A 91:8822-8826
76. Zhou DC, Marie JP, Suberville AM, Zittoun R (1992) Relevance of mdr1 gene expression in acute myeloid leukemia and comparison of different diagnostic methods. Leukemia 6:879-885
77. Zochbauer S, Gsur A, Brunner R, Kryle PA, Lechner K, Pirker R (1994) P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. Leukemia 8:974-977